SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peter, Nirula, Ajay, Heller, Barry, Gottlieb, Robert L., Boscia, Joseph, Morris, Jason, Huhn, Gregory, Cardona, Jose, Mocherla, Bharat, Stosor, Valentina, Shawa, Imad, Adams, Andrew C., Van Naarden, Jacob, Custer, Kenneth L., Shen, Lei, Durante, Michael, Oakley, Gerard, Schade, Andrew E., Sabo, Janelle, Patel, Dipak R., Klekotka, Paul, Skovronsky, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646625/
https://www.ncbi.nlm.nih.gov/pubmed/33113295
http://dx.doi.org/10.1056/NEJMoa2029849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646625/
https://www.ncbi.nlm.nih.gov/pubmed/33113295
http://dx.doi.org/10.1056/NEJMoa2029849

Ejemplares similares